口服药物递送市场－全球产业规模、份额、趋势、机会和预测，按剂型、类型、治疗领域、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球口服药物递送市场规模为1,297.7亿美元，预计到2030年将以7.80%的复合年增长率成长至2,036.5亿美元。全球口服药物递送市场涵盖了製药业中致力于开发、生产和销售口服给药治疗药物的细分领域。与其他给药方式相比，口服给药因其固有的便利性、易于给药以及更高的患者依从性而备受青睐。推动该市场成长的关键因素包括心血管疾病、糖尿病和癌症等慢性疾病在全球范围内的日益普遍，这些疾病需要长期服药治疗。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球口服药物递送市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依剂型（锭剂、胶囊、滴剂、液体或糖浆）分类
  • 按类型（控释片、口腔崩解片、其他）
  • 依治疗领域（肿瘤科、肌肉骨骼科、免疫科、胃肠科、呼吸科、心血管科、其他）
  • 按最终使用者（医院、门诊手术中心、诊断中心、诊所、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美口服药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲口服药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区口服药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲口服药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲口服药物递送市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球口服药物传递市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Novartis AG
• Biocon Ltd.
• NovoNordisk A/S
• F.Hoffmann-La Roche Ltd.
• Bayer AG
• Emishphere Technologies Inc.
• Enteris Biopharma Inc.
• Merrion Pharmaceuticals Plc.
• Amgen Inc.
• Pfizer Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Oral Drug Delivery Market, valued at USD 129.77 Billion in 2024, is projected to experience a CAGR of 7.80% to reach USD 203.65 Billion by 2030. The Global Oral Drug Delivery Market encompasses the segment of the pharmaceutical industry dedicated to developing, manufacturing, and commercializing therapeutic agents administered via the oral route. This method is highly favored due to its inherent patient convenience, ease of administration, and potential for improved compliance compared to other delivery methods. Key drivers propelling this market include the increasing global prevalence of chronic diseases such as cardiovascular conditions, diabetes, and cancer, which necessitate long-term medication regimens.

Key Market Drivers

Technological advancements in drug delivery systems and expanded investment in pharmaceutical research and development exert considerable influence on the Global Oral Drug Delivery Market. Innovations in solubility enhancement, controlled release mechanisms, and targeted delivery are broadening the range of orally administered therapies, including complex molecules once limited to injectable routes. These developments improve drug stability, bioavailability, and therapeutic precision. For instance, according to Fierce Biotech, in April 2025, Roche acquired Carmot Therapeutics for $2.7 billion in late 2023, securing access to three GLP-1 receptor agonists with potential for treating obesity, including oral administration. Such strategic investments emphasize the industry's dedication to patient-friendly oral formulations.

Key Market Challenges

A significant challenge impeding market expansion for oral drug delivery is the stringent regulatory approval processes. These complex procedures inherently increase the time and financial investment required to bring new oral formulations to market. This extended development timeline and heightened cost create substantial barriers for pharmaceutical companies, particularly those developing innovative therapies, by prolonging the period before potential revenue generation.

Key Market Trends

The development of personalized oral therapies is a significant trend reshaping the Global Oral Drug Delivery Market by moving towards treatments tailored to individual patient profiles. This approach leverages advancements in diagnostics and genomics to customize drug selection, dosage, and formulation, enhancing therapeutic efficacy and minimizing adverse effects. According to the Personalized Medicine Coalition (PMC), in 2024, the FDA approved 18 new personalized medicines, representing approximately 38 percent of all newly approved therapeutic molecular entities. These approvals underscore a growing industry commitment to individualized treatment pathways.

Key Market Players

• Novartis AG
• Biocon Ltd.
• NovoNordisk A/S
• F.Hoffmann-La Roche Ltd.
• Bayer AG
• Emishphere Technologies Inc.
• Enteris Biopharma Inc.
• Merrion Pharmaceuticals Plc.
• Amgen Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Oral Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Drug Delivery Market, By Formulation:

• Tablets
• Capsules
• Drops
• Liquid or Syrup

Oral Drug Delivery Market, By Type:

• Controlled Release
• Orodispersible Tablets
• Others

Oral Drug Delivery Market, By Therapy Area:

• Oncology
• Musculoskeletal
• Immunology
• Gastrointestinal
• Respiratory
• Cardiovascular
• Others

Oral Drug Delivery Market, By End User:

• Hospitals
• Ambulatory Surgical Centres
• Diagnostic Centres
• Clinics
• Others

Oral Drug Delivery Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oral Drug Delivery Market.

Available Customizations:

Global Oral Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Drug Delivery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Formulation (Tablets, Capsules, Drops, Liquid or Syrup)
  • 5.2.2. By Type (Controlled Release, Orodispersible Tablets, Others)
  • 5.2.3. By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others)
  • 5.2.4. By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres, Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Oral Drug Delivery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Formulation
  • 6.2.2. By Type
  • 6.2.3. By Therapy Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Drug Delivery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Formulation
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Therapy Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Oral Drug Delivery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Formulation
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Therapy Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Oral Drug Delivery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Formulation
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Therapy Area
      • 6.3.3.2.4. By End User

7. Europe Oral Drug Delivery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Formulation
  • 7.2.2. By Type
  • 7.2.3. By Therapy Area
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Drug Delivery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Formulation
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Therapy Area
      • 7.3.1.2.4. By End User
  • 7.3.2. France Oral Drug Delivery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Formulation
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Therapy Area
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Oral Drug Delivery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Formulation
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Therapy Area
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Oral Drug Delivery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Formulation
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Therapy Area
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Oral Drug Delivery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Formulation
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Therapy Area
      • 7.3.5.2.4. By End User

8. Asia Pacific Oral Drug Delivery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Formulation
  • 8.2.2. By Type
  • 8.2.3. By Therapy Area
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oral Drug Delivery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Formulation
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Therapy Area
      • 8.3.1.2.4. By End User
  • 8.3.2. India Oral Drug Delivery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Formulation
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Therapy Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Oral Drug Delivery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Formulation
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Therapy Area
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Oral Drug Delivery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Formulation
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Therapy Area
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Oral Drug Delivery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Formulation
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Therapy Area
      • 8.3.5.2.4. By End User

9. Middle East & Africa Oral Drug Delivery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Formulation
  • 9.2.2. By Type
  • 9.2.3. By Therapy Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oral Drug Delivery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Formulation
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Therapy Area
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Oral Drug Delivery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Formulation
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Therapy Area
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Oral Drug Delivery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Formulation
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Therapy Area
      • 9.3.3.2.4. By End User

10. South America Oral Drug Delivery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Formulation
  • 10.2.2. By Type
  • 10.2.3. By Therapy Area
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oral Drug Delivery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Formulation
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Therapy Area
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Oral Drug Delivery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Formulation
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Therapy Area
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Oral Drug Delivery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Formulation
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Therapy Area
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oral Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biocon Ltd.
• 15.3. NovoNordisk A/S
• 15.4. F.Hoffmann-La Roche Ltd.
• 15.5. Bayer AG
• 15.6. Emishphere Technologies Inc.
• 15.7. Enteris Biopharma Inc.
• 15.8. Merrion Pharmaceuticals Plc.
• 15.9. Amgen Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer